Hepatitis C News and Research

Latest Hepatitis C News and Research

MinuteClinic re-accredited and earns the Joint Commission's Gold Seal of Approval

MinuteClinic, the retail health care division of CVS Caremark (NYSE: CVS) and the pioneer and largest provider of retail-based medical clinics in the United States, has become the first retail clinic to be re-accredited and earn the Joint Commission's Gold Seal of Approval(TM) for consecutive evaluation periods by having demonstrated compliance with The Joint Commission's national standards for health care quality and safety.

9 Jan 2010

Novelos Therapeutics to conclude pivotal Phase 3 trial in advanced non-small cell lung cancer

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the 725th event (patient death) has been reached in its pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy.

8 Jan 2010

ZymoGenetics announces pricing of public offering of 14,000,000 shares

ZymoGenetics, Inc. today announced that it has priced an underwritten public offering of 14,000,000 shares of its common stock at a price of $6.00 per share. Net proceeds, after estimated underwriting discounts and commissions and estimated expenses, will be approximately $79,000,000.

8 Jan 2010

Life-saving therapeutic interventions possible with early detection of hepatitis C recurrence

A recent study by doctors from the Hospital Cl-nic in Barcelona, Spain determined that repeated liver stiffness measurements (LSM) in the first year following liver transplant (LT) could discriminate between slow and rapid "fibrosers" (patients with fibrosis stage of F2-F4 one year post LT).

6 Jan 2010

Quercetin may prevent hepatitis C infection; findings may lead to less toxic treatments

Researchers have identified two cellular proteins that are important factors in hepatitis C virus infection, a finding that may result in the approval of new and less toxic treatments for the disease, which can lead to liver cancer and cirrhosis.

6 Jan 2010

Increased coffee consumption linked to reduced hepatic fibrosis

Researchers from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) determined that patients with chronic hepatitis C virus (HCV) who consumed more than 308 mg of caffeine daily had milder liver fibrosis. The daily amount of caffeine intake found to be beneficial is equivalent to 2.25 cups of regular coffee.

5 Jan 2010

Children’s vaccination coverage rises substantially in U.S.

About three-quarters of U.S. children received recommended vaccinations in 2008, up from about half in 2000, reports a new study from the Centers for Disease Control and Prevention (CDC).

5 Jan 2010

Peginterferon alpha-2a yields better results in treating patients with chronic hepatitis C

In patients with chronic hepatitis C, treatment with peginterferon alpha-2a (PegIFNα2a) plus ribavirin (RBV) better suppresses the virus to undetectable levels in the blood than treatment with peginterferon alpha-2b (PegIFNα2b) plus RBV, according to two new head-to-head studies in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

5 Jan 2010

FDA grants Priority Review designation for InterMune's NDA for pirfenidone

InterMune, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review and granted Priority Review designation for the company's New Drug Application (NDA) for pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF).

4 Jan 2010

Sharing Miracles: A TV program that features inspirational stories of real patients

Major League Baseball slugger Aaron Boone will be featured on January's episode of Sharing Miracles - a 30-minute public affairs television program that tells the compelling and inspirational stories of real patients. Sharing Miracles airs every week on more than 300 television stations nationwide.

31 Dec 2009

Chlorophyll and chlorophyllin effective in limiting aflatoxin absorption in humans

A new study has found that chlorophyll and its derivative chlorophyllin are effective in limiting the absorption of aflatoxin in humans. Aflatoxin is produced by a fungus that is a contaminant of grains including corn, peanuts and soybeans; it is known to cause liver cancer - and can work in concert with other health concerns, such as hepatitis.

30 Dec 2009

Xin Aoxing Oleanolic Acid Capsules for treatment of Hepatitis B to be launched

Biostar Pharmaceuticals, Inc. ("Biostar" or "the Company"), a Xianyang-based developer, manufacturer and supplier of pharmaceutical products and medical nutrients addressing a variety of diseases and conditions, today announced it has completed preparation to launch its flagship Xin Aoxing Oleanolic Acid ("Xin Aoxing") Capsules for the treatment of Hepatitis B in Beijing and Shanghai in early January 2010.

29 Dec 2009

Food Safety News lists its top ten ten food safety stories of 2009

Food Safety News, the web-based newspaper that covers all things food safety, today published its list of the top ten food safety stories of the year.

29 Dec 2009

Tripep’s rights offering oversubscribed

The preliminary result from Tripep’s rights offering shows that it has been oversubscribed with significant marginal (approximately 150%). Through the offering Tripep will receive approximately 17.8 MSEK before emission costs. The final outcome of the emission will be presented around the 30th of December 2009.

23 Dec 2009

Newly identified targets in treating inflammatory disorders of the gastrointestinal tract

Digestive-disease-associated mortality accounts for a major part of all deaths in Western societies and inflammatory diseases such as GI infections, viral hepatitis, GERD or cancers due to chronic inflammation have a tangible economic and social impact.

22 Dec 2009

ZymoGenetics restructures license and collaboration agreements on RECOTHROM

ZymoGenetics, Inc. today announced a restructuring of the U.S. co-promotion and ex-U.S. license and collaboration agreements with Bayer Schering Pharma AG and Bayer HealthCare relating to RECOTHROM® Thrombin, topical (Recombinant).

21 Dec 2009

Positive interim results from Idera Pharmaceuticals' IMO-2125 Phase 1 clinical trial for HCV

Idera Pharmaceuticals, Inc. today announced positive interim results from a Phase 1 clinical trial of IMO-2125 in patients with chronic hepatitis C virus infection (HCV). IMO-2125 is an agonist of Toll-like Receptor 9 that Idera designed to treat HCV by inducing endogenous interferon-alpha and other Th1-type cytokines and chemokines.

21 Dec 2009

Swedish agency approves Medivir's Xerclear for treatment of cold sores

The Swedish Medical Products Agency has now approved Xerclear™ for treatment of cold sores. It is the first and only topical treatment that has been demonstrated to prevent the incidence of cold sores and shorten healing-times. Xerclear™ will be available from pharmacies in the first half-year 2010.

21 Dec 2009

EMA's CHMP issues positive opinion for Cangene's Human Hepatitis B Immunoglobulin product

Cangene Corporation today reports that it has received a positive opinion from the EMA's Committee for Medicinal Products for Human Use ("CHMP") regarding the immunoprophylaxis indication of Cangene's ImmunoGam(TM) (Human Hepatitis B Immunoglobulin).

18 Dec 2009

Flamel Technologies initiates IFN-alpha-2b XL Phase 2a clinical trial for HCV

Flamel Technologies today announced the initiation of a Phase 2a clinical trial of Flamel’s Interferon alpha-2b XL (IFN-alpha-2b XL), which is based on Flamel’s Medusa® platform for controlled release of biologics. IFN-alpha-2b XL is being developed as a controlled release of unmodified interferon alpha-2b for the treatment of chronic hepatitis C virus (HCV).

18 Dec 2009

Hepatitis C News and Research

Latest Hepatitis C News and Research

MinuteClinic re-accredited and earns the Joint Commission's Gold Seal of Approval

Novelos Therapeutics to conclude pivotal Phase 3 trial in advanced non-small cell lung cancer

ZymoGenetics announces pricing of public offering of 14,000,000 shares

Life-saving therapeutic interventions possible with early detection of hepatitis C recurrence

Quercetin may prevent hepatitis C infection; findings may lead to less toxic treatments

Increased coffee consumption linked to reduced hepatic fibrosis

Children’s vaccination coverage rises substantially in U.S.

Peginterferon alpha-2a yields better results in treating patients with chronic hepatitis C

FDA grants Priority Review designation for InterMune's NDA for pirfenidone

Sharing Miracles: A TV program that features inspirational stories of real patients

Chlorophyll and chlorophyllin effective in limiting aflatoxin absorption in humans

Xin Aoxing Oleanolic Acid Capsules for treatment of Hepatitis B to be launched

Food Safety News lists its top ten ten food safety stories of 2009

Tripep’s rights offering oversubscribed

Newly identified targets in treating inflammatory disorders of the gastrointestinal tract

ZymoGenetics restructures license and collaboration agreements on RECOTHROM

Positive interim results from Idera Pharmaceuticals' IMO-2125 Phase 1 clinical trial for HCV

Swedish agency approves Medivir's Xerclear for treatment of cold sores

EMA's CHMP issues positive opinion for Cangene's Human Hepatitis B Immunoglobulin product

Flamel Technologies initiates IFN-alpha-2b XL Phase 2a clinical trial for HCV

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in